ReviewBiomolecules2019
Albumin Nanovectors in Cancer Therapy and Imaging.
Review in Biomolecules, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systematic Review of Cancer Targeting by Nanoparticles Revealed a Global Association between Accumulation in Tumors and Spleen.International journal of molecular sciences · 2021Pooled it
- Amino Oxidase Hard Protein Corona with Metabolic-Triggered Intracellular Biocatalysis.International journal of molecular sciences · 2026Article
- Probing the Interaction Between Thioacetamide Fungicide and Bovine Serum Albumin Through Fluorescence, Electrochemical, and Docking Analyses.Luminescence : the journal of biological and chemical luminescence · 2026Article
- Albumin Nanoparticles as Multifunctional Carriers for Advanced Therapeutics.Pharmaceutics · 2026Review
- The prognostic role of inflammation-based hematologic markers in stage I-III colorectal cancer: a retrospective analysis.BMC cancer · 2025Article
- Prognostic significance of the CALLY index for cancer risk and survival: evidence from NHANES 2001-2018.World journal of surgical oncology · 2025Article
- Interaction Mechanisms of KRAS G12C Inhibitors (Sotorasib and Adagrasib) with Human Serum Albumin: Insights from Spectroscopic and Molecular Docking Studies.Molecules (Basel, Switzerland) · 2025Article
- An in-vitro and in-silico approaches in exploring the molecular contact of COVID-19 antiviral drug molnupiravir with human serum albumin: effect of binding on protein structure.Journal of computer-aided molecular design · 2025Article
- Breaking barriers: Smart vaccine platforms for cancer immunomodulation.Cancer communications (London, England) · 2025Review
- Spectroscopic and molecular docking studies on binding interactions of camptothecin drugs with bovine serum albumin.Scientific reports · 2025Article
- Prognostic value of combined systemic inflammation response index and prognostic nutritional index in colorectal cancer patients.World journal of gastrointestinal surgery · 2024Article
- Tocopherol-human serum albumin nanoparticles enhance lapatinib delivery and overcome doxorubicin resistance in breast cancer.Nanomedicine (London, England) · 2024Article
- Contrast Agents Based on Human Serum Albumin and Nitroxides forInternational journal of molecular sciences · 2024Article
- Chitosan-Albumin Nanocomposite as a Promising Nanocarrier for Efficient Delivery of Fluconazole Against Vaginal Candidiasis.Applied biochemistry and biotechnology · 2024Article
- Predictive value of serum albumin levels on cancer survival: a prospective cohort study.Frontiers in oncology · 2024Article
- Recent advances in drug delivery of celastrol for enhancing efficiency and reducing the toxicity.Frontiers in pharmacology · 2024Review
- Use of Albumin for Drug Delivery as a Diagnostic and Therapeutic Tool.Current pharmaceutical biotechnology · 2024Review
- Review
- Proteolytic Resistance Determines Albumin Nanoparticle Drug Delivery Properties and Increases Cathepsin B, D, and G Expression.International journal of molecular sciences · 2023Article
- Safety of Gold Nanoparticles: From In Vitro to In Vivo Testing Array Checklist.Pharmaceutics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Albumin nanovectors represent one of the most promising carriers recently generated because of the cost-effectiveness of their fabrication, biocompatibility, safety, and versatility in delivering hydrophilic and hydrophobic therapeutics and diagnostic agents. In this review, we describe and discuss the recent advances in how this technology has been harnessed for drug delivery in cancer, evaluating the commonly used synthesis protocols and considering the key factors that determine the biological transport and the effectiveness of such technology. With this in mind, we highlight how clinical and experimental albumin-based delivery nanoplatforms may be designed for tackling tumor progression or improving the currently established diagnostic procedures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.